Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43DC.A.TO 0.3NESN-SIX 0MCK 31.3
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Mar 03, 2008
(Market Call Minute.) At this price, you can be a buyer and sell at $26 or so.
Photo of John O'Connell, CFAJohn O'Connell, CFAUnlock Rating
$22.25

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 27, 2008
He has a model price of $40.10, which is a 76% positive differential. Has up its dividends considerably and has positive earnings revisions.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.75

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 20, 2008
Their pipeline has just not produced new drugs. When you buy this stock now, you are getting a series of cash flows on the existing drugs, but a lot of them are coming off patent. Just acquired a company that has a very small drug, which to him, is a sign of desperation.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$22.47

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2008
This is the worst of times for giant pharmaceutical companies. Now spending more on marketing than they are on research/development. Ongoing huge costs of developing new drugs that are safe are a drag. Also, cost of litigation remains a huge burden. Probably safer with the generic companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$22.37

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 11, 2008
Has a 2-pronged approach to the drug industry with Teva Pharmaceuticals (TEVA-Q) as his growth generic company and this one as his value dividend play. It is giving great income until their pipeline improves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.20

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 07, 2008
(A Top Pick Feb 1/07. Down 10% including dividends.) This one has been the bane of all value managers. His model price is $37.57, a 66% positive differential. This one needs a catalyst.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.67

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 10, 2008
(A Top Pick Dec 18/06. Down 7.4%.) Got decimated when they lost a lawsuit on Lipitor. Sold his holdings.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
No
Unlock Rating
$24.08

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2008
This sector does well in a slowing economy. 5.6% yield. Has a war chest of almost $30 million in cash to be used for acquisitions. Share buybacks keep increasing the dividends. Mid/long-term pipeline is very promising. Yield and cash limit downside risk. A lot of potential upside surprises.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.23

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 20, 2007
(A Past Top Pick Dec 21/06. Down 10.8%.) This one is probably the bane of all the value managers. Even boosted their dividend by 10%. His model price is $40.53, a 74% positive differential. If they could do anything to thin out that balance sheet, it would be a huge positive for the stock.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.22

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 19, 2007
He threw in the towel last quarter and sold his holdings. The problem is they just haven't been developing new drugs and as time goes by, you get closer to patent expiration.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$23.27

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 18, 2007
Big questions with drug companies are “How big is their pipeline of drugs and development?” “What’s the patent life of their big drugs?” and “How vulnerable are they to erosion from generics?”.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$23.37

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 12, 2007
Pharma as an industry as a model is really at a crossroads. The chemical-based side is giving way to the biology-side of science. They have a lot of money, but do not have a good pipeline. The biology side is just the opposite. They have the largest phase 2 pipeline that they've ever had and that could translate by 2009 into the biggest phase 3. They own some, but are tempted to pull the plug.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$23.81

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 03, 2007
(A Past Top Pick. Dec 5/06. Down 4.8%.) 5% yield is why he still likes it. All of the bad news is basically known. Sold their consumer products division for $19 billion and will use the cash for acquisitions, share buybacks, dividend increases and increase research. Recession resistant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.55

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Nov 30, 2007
It has all the value characteristics that he loves. Has a lot of net cash. Very cheap. Concerned about administration changes when the US election occurs and that their biggest selling drug Lipitor is about 30% of their sales.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$23.76

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(A Top Pick Dec 26/06. Down 12.6%.) Still undervalued. Hopefully there’s pressure on management to do something. His model price is $38.27. a 68.5% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 541 to 555 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

IESC -10.89$313.23
NTR.TO -2.19$100.68
TFPM 0$
OGC.TO 0.08$43.3
SLB -0.71$53.29
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

MNT.TO 0.69$69.95
COPX 1.79$96.32
U.U.TO 0.5$20.92
SII.TO 2.94$190.13
IPCO.TO -0.43$34.79

Popular Articles

Latest Sell Signals

RKLB -1.37$66.91
INTC 0.22$87.48
MSFT 4.4$491.71
WSP.TO -2.98$189.3
CLS.TO 16.21$423.57

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like